DGIdb 5.0: rebuilding the drug–gene interaction database for precision medicine and drug discovery platforms

Author:

Cannon Matthew1ORCID,Stevenson James1,Stahl Kathryn1,Basu Rohit1,Coffman Adam2ORCID,Kiwala Susanna2ORCID,McMichael Joshua F2ORCID,Kuzma Kori1,Morrissey Dorian2,Cotto Kelsy2ORCID,Mardis Elaine R13,Griffith Obi L2ORCID,Griffith Malachi2ORCID,Wagner Alex H13ORCID

Affiliation:

1. Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital , Columbus , OH 43205 , USA

2. Department of Medicine, Washington University , St Louis , MO 63110 , USA

3. Department of Pediatrics, The Ohio State University College of Medicine , Columbus , OH 43210 , USA

Abstract

Abstract The Drug–Gene Interaction Database (DGIdb, https://dgidb.org) is a publicly accessible resource that aggregates genes or gene products, drugs and drug–gene interaction records to drive hypothesis generation and discovery for clinicians and researchers. DGIdb 5.0 is the latest release and includes substantial architectural and functional updates to support integration into clinical and drug discovery pipelines. The DGIdb service architecture has been split into separate client and server applications, enabling consistent data access for users of both the application programming interface (API) and web interface. The new interface was developed in ReactJS, and includes dynamic visualizations and consistency in the display of user interface elements. A GraphQL API has been added to support customizable queries for all drugs, genes, annotations and associated data. Updated documentation provides users with example queries and detailed usage instructions for these new features. In addition, six sources have been added and many existing sources have been updated. Newly added sources include ChemIDplus, HemOnc, NCIt (National Cancer Institute Thesaurus), Drugs@FDA, HGNC (HUGO Gene Nomenclature Committee) and RxNorm. These new sources have been incorporated into DGIdb to provide additional records and enhance annotations of regulatory approval status for therapeutics. Methods for grouping drugs and genes have been expanded upon and developed as independent modular normalizers during import. The updates to these sources and grouping methods have resulted in an improvement in FAIR (findability, accessibility, interoperability and reusability) data representation in DGIdb.

Funder

National Human Genome Research Institute

Publisher

Oxford University Press (OUP)

Subject

Genetics

Reference24 articles.

1. DGIdb: mining the druggable genome;Griffith;Nat. Methods,2013

2. The druggable genome;Hopkins;Nat. Rev. Drug Discov.,2002

3. The druggable genome: an update;Russ;Drug Discov. Today,2005

4. DGIdb 2.0: mining clinically relevant drug–gene interactions;Wagner;Nucleic Acids Res.,2016

5. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database;Cotto;Nucleic Acids Res.,2017

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3